An observational study in Depression / Major Depressive Disorder and Anxiety, sponsored by Kintsugi Mindful Wellness, Inc.. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Kintsugi Mindful Wellness, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,709 studies in Depression with a site in United States — 578 open to participants now, 717 under way, 30 of them phase 3. Depression · United States.
Among the 3,709 studies in Depression with a site in United States, this one is the 2nd largest by enrollment of the 371 observational ones that give a count, is one of 184 that started in 2019, is one of 372 observational ones, and was the 3,663rd registered.
8,582 studies on the registry are indexed under Depression; 1,723 are open to participants now.
Browse Depression studies →578 of the 3,709 studies in Depression with a site in United States are open now. Recruiting first, the newest first:
Children's Mercy Hospital Kansas City · Sites in United States
Ages 13–17
NeuroRx, Inc. · Sites in United States
Ages 18–80
Ohio State University · Sites in United States
Ages 21–65
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
University of Texas Southwestern Medical Center · Sites in United States
Ages 12–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,089 Depression studies recruiting now, 470 (43%) set no upper age limit and 519 (48%) stop at 75 or younger; 203 take children under 18; 311 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,709 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 235 · Phase 2 441 · Phase 3 285 · Phase 4 265
First in 1977; this study’s year is marked. 184 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50,000 is above the median of 175 across 1,259 observational studies indexed under Depression.
Median enrollment 72 across the 3,316 interventional studies, 138 across the 371 observational. Of the 2,761 that completed or were terminated, 1,045 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
392 of 3,709 have an industry lead sponsor. The 10 most frequent:
Kintsugi Mindful Wellness, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Kintsugi Mindful Wellness, Inc. has 5 studies filed under Depression — fewer than ten, so there is no comparison to draw.
299 of the studies in Depression with a site in United States that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT05474846Phase 3M.D. Anderson Cancer CenterCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer | 2027-02-28 |
| NCT04777357Phase 3AbbVieA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | 2027-03 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 299 to your calendar (.ics) → With an account.
Among the 3,709 studies in Depression with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This retrospective observational study evaluated the relationship between voice characteristics and self-reported mental health symptoms using longitudinal data collected through the Kintsugi Voice Journaling app. Participants provided voice recordings and completed the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) over time. The study analyzed previously collected data to evaluate whether voice biomarkers could be associated with symptoms of depression and anxiety.
This retrospective observational cohort study analyzed previously collected longitudinal data from users of the Kintsugi Voice Journaling app. Participants voluntarily recorded voice samples through the app and completed standardized self-report measures of depression and anxiety, including the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7), over a period of several years.
The study population included individuals who used the Kintsugi Voice Journaling app and contributed voice recordings and mental health questionnaire data. No intervention was assigned as part of this study, and no additional data were collected specifically for the research analysis.
The analysis evaluated associations between features derived from participants' voice recordings and self-reported symptoms of depression and anxiety. The study was conducted using previously collected observational data from approximately 50,000 participants.
The study population consisted of users of the Kintsugi Voice Journaling app, a mobile application available globally, who had previously contributed voice recordings and self-reported mental health questionnaire data during routine use of the application. Participants were not recruited at a physical study site; all data were contributed remotely through the app. No participants meeting the inclusion criteria were excluded from the analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- None; no participants meeting the inclusion criteria were excluded from the analysis
Individuals who used the Kintsugi Voice Journaling app and contributed voice recordings along with self-reported PHQ-9 and/or GAD-7 assessments during routine use of the application. No intervention was assigned as part of this study; all data were collected previously during routine app use and analyzed retrospectively.
Association Between Voice Biomarkers and Depressive Symptom Severity (PHQ-9)
Association between voice biomarkers and depressive symptom severity as measured by the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a 9-item self-report measure of depressive symptom severity; each item is scored 0-3 and total scores range from 0 to 27, with higher scores indicating greater (worse) depressive symptom severity.
Time frame: Through study completion, up to 24 months
Association Between Voice Biomarkers and Anxiety Symptom Severity (GAD-7)
Association between voice biomarkers and anxiety symptom severity as measured by the Generalized Anxiety Disorder-7 (GAD-7). The GAD-7 is a 7-item self-report measure of anxiety symptom severity; each item is scored 0-3 and total scores range from 0 to 21, with higher scores indicating greater (worse) anxiety symptom severity.
Time frame: Through study completion, up to 24 months
Plan to share: No — Individual participant data will not be shared. The dataset consists of voice recordings, which are inherently identifiable and cannot be reliably de-identified, together with associated self-reported mental health assessments.
No publications or documents are linked to this record.
Ran from Oct 2019 to primary completion in Oct 2021, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kintsugi Mindful Wellness, Inc.